Kymera Therapeutics stock edged up about 1% to US$105.48 after the Q2 print, a muted move for a biotech reporting US$65m in collaboration revenue and another quarter of sizeable losses. The market seems to be treating this as a steady, low drama update rather than a breakout moment.

The key point for investors is the widening gap between a partnership-driven top line and continuing net losses of more than US$60m for the quarter. With cash of about US$1.5b and no more collaboration revenue expected this year without new milestones, the focus now is on how long patience will last for this level of spending to translate into durable value.

Is Kymera Therapeutics stock starting to look mispriced as losses persist while revenue forecasts stay upbeat, or is the current valuation already reflecting that? Compare where NasdaqGM:KYMR trades versus peers on our valuation analysis for Kymera Therapeutics

Q2 2026 Earnings Summary

• Revenue, Q2 2026 vs Q2 2025: US$65.0m vs. US$11.5m (large increase driven by collaboration revenue)
• Net Loss, Q2 2026 vs Q2 2025: US$61.2m loss vs. US$76.6m loss (loss narrowed)
• Basic EPS, Q2 2026 vs Q2 2025: US$0.62 loss per share vs. US$0.95 loss per share (loss per share narrowed)
• Trailing 12 Month Net Loss, Q2 2026 vs Q2 2025: US$299.6m loss vs. US$275.4m loss (loss widened over the year)

Prefer clean, visual charts instead of a dense wall of biotech earnings tables and spreadsheets? See Kymera Therapeutics' full financial picture, along with a clear view of its valuation setup, in the company report for Kymera Therapeutics.

Kymera bull case leans on execution milestones

Bulls argue Kymera can turn its protein degrader platform into an oral immunology franchise, with KT‑621 leading the way and KT‑579 and partnered programs adding proof points. Q2 hits several of those execution milestones. BROADEN‑2 enrollment finished about six months early, which supports the claim that KT‑621 is gaining operational momentum and brings the atopic dermatitis data timing into year end 2026. The asthma BREADTH Phase 2b remains on timetable and an open label extension is underway, which aligns with the story of building a late stage package. KT‑579 is on track for Q4 2026 healthy volunteer data, with clear pharmacodynamic goals laid out. KT‑485 has entered Phase 1 and triggered a US$20m milestone, while Gilead’s KT‑200 option fee added US$45m. Combined with a cash runway into 2029, the bullish narrative of platform progress and funded execution is largely supported by this quarter.

Kymera bear case focuses on losses and dependency

Bears worry that Kymera is burning heavy cash on a concentrated bet in KT‑621, with limited line of sight to recurring revenue. Q2 results give those concerns some traction. Collaboration revenue of US$65m is tied to one time Gilead and Sanofi payments. Management has already said no further 2026 revenue is expected without new milestones, which underlines how dependent the income line is on partners. At the same time, R&D cash spend is about US$109.1m in the quarter, G&A adds another US$12.5m, and the company reported a quarterly net loss of US$61.2m with a trailing 12 month loss of US$299.6m. The share price response, up about 1% after earnings and down 11.5% over 30 days, indicates the market is not treating this as a clear breaking point for the bear case, but the persistence of high losses and legal investigations keeps that narrative alive.

After heavy cash burn, a one-time milestone revenue event and recent shareholder dilution, scan our independent risk analysis for Kymera Therapeutics which shows 3 important warning signs to expose further structural vulnerabilities.

Stay Ahead With Kymera Insights

If the mix of Kymera Therapeutics’ heavy R&D spend, one time milestone revenue and ongoing losses has you watching for a better entry point, register for free with Simply Wall St and add it to a Watchlist to track the share price against fair value and upcoming catalysts. Once you own any stock, keep your next moves clearer by using the Portfolio Command Center to cut through noise and surface only the most important developments for your holdings. For a longer term view, tap into the Community to see how other investors are thinking about risks, execution and potential turning points. By spotting hidden catalysts and red flags early, you can make faster, more confident decisions and stay a step ahead of the market.

Seeking Alternatives Beyond Kymera Therapeutics?

Fresh stock ideas can move from quiet to breakout fast. Momentum shifts, prices fly or drop, and signals fade before the crowd notices. Scan these picks and act now.

• Spot cash rich companies with room to grow faster than expectations by running the curated list of solid balance sheet and fundamentals stocks (50 results) while those balance sheets are still under the radar.
• Track potential breakout payouts from companies built to sustain high yields with the hand picked 8 dividend fortresses before income focused buyers crowd the trade.
• Ride real business momentum in AI by zeroing in on the 67 profitable AI stocks that aren't just burning cash so you are focused on companies that already generate cash, not just stories.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.